DKS Co., Ltd. (4461) AI Stock Analysis

• Market Cap: ¥80.10B
• Dividend Yield: 1.24%
• Average Volume (3M): 144.71K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 1.36
• Revenue Growth: 8.78%
• EPS Growth: 19.37%
• Country: JP
• Employees: 1,111
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 198.02
• Shares Outstanding: 10,684,321
• 10 Day Avg. Volume: 174,660
• 30 Day Avg. Volume: 144,713
• PEG Ratio: 0.08
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.36
• P/FCF Ratio: 4.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 439.4
• Revenue Forecast (FY): ¥79.00B

• Rating: 63 Neutral
• Price Target: ¥8,062.00 ▼(-2.04% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is driven primarily by improving financial performance and cash generation, supported by a low P/E valuation. These positives are tempered by weak technical momentum (price below key moving averages and negative MACD), indicating near-term market pressure despite oversold readings.

Positive Factors

Revenue and Margin Expansion

Sustained double-digit revenue growth with simultaneous margin expansion indicates rising product demand and improving cost control. Over the next 2–6 months this combination supports durable operating leverage, better cash generation and greater reinvestment capacity for product or capacity expansion.

Strong Cash Generation

High OCF-to-net-income and rising free cash flow show the business converts earnings to cash efficiently. This strengthens funding for capex, working capital and potential deleveraging or strategic investments, improving financial flexibility and resilience across business cycles.

Manageable Leverage and Equity Base

A moderate debt-to-equity and near-40% equity ratio point to a conservative capital structure, reducing default risk and preserving borrowing capacity. This structural balance supports steady investment and cushions volatility, enabling sustained operations and strategic initiatives.

Negative Factors

Modest Net Profitability

Net margin remains low in absolute terms, limiting the firm's margin of safety against input cost shocks or demand dips. Over months this constrains the ability to self-fund larger strategic initiatives and leaves less room for sustained margin improvement without continued revenue growth or structural cost reductions.

Limited Return on Equity

An ROE in the mid-single digits signals modest capital efficiency versus higher-return peers. Persistently low ROE can restrict shareholder value creation and may require either operational improvement or higher growth to meaningfully lift returns over a multi-quarter horizon.

Earnings Sensitivity / Volatility

A beta above 1 implies business results and equity value are relatively cyclical or sensitive to macro swings. Structurally this raises execution risk for multi-quarter planning, potentially magnifying margin and cash-flow variability during economic slowdowns that affect specialty chemical demand.

DKS Co., Ltd. Business Overview & Revenue Model

Company Description

DKS Co. Ltd. produces and sells surfactants and other industrial chemicals for various industries in Japan and internationally. It operates through six segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. The company offers nonionic, anionic, cationic, polymerizable, and amphoteric surfactants, as well as formulated surfactant blends; and amenity materials, including sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, industrial deodorants, and other products. It also provides polyurethane materials, such as polyether polyol, urethane prepolymer, and urethane systems; functional materials comprising radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants; and electronic device materials that include ionic liquids, ion-conductive polymers, and ceramic/metal injection molding materials, as well as conductive pastes for electronics, injection molding pellets, and functional inorganic materials. Further, the company supplies health food products that include an I. Japonica-Bombyx Fungus dietary supplement; and Sudachin, a peel extract powder made from citrus fruit. DKS Co. Ltd was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. and changed its name to DKS Co. Ltd. in 2013. The company was founded in 1909 and is headquartered in Kyoto, Japan.

How the Company Makes Money

null

DKS Co., Ltd. Financial Statement Overview

Summary

Financials show a clear FY2025 recovery: stronger profitability/margins (Income Statement score 71) and improved cash generation with positive free cash flow in the last two years (Cash Flow score 68). Offsetting this, leverage remains meaningful and profitability has been inconsistent across years (Balance Sheet score 62; prior loss and uneven revenue growth).

Income Statement

Profitability rebounded strongly in FY2025, with revenue up ~2% and a meaningful step-up in operating and net margins versus FY2024, reversing the FY2023 loss year. Gross margin also improved back near prior-cycle levels. The main weakness is consistency: revenue growth has been uneven over the period and earnings volatility (including a loss in FY2023) lowers confidence in through-cycle stability.

Balance Sheet

Leverage is moderate for the sector, with debt-to-equity improving in FY2025 versus FY2024 as equity grew and debt declined. Returns on equity also recovered to mid-single-digits after a weak FY2023–FY2024 stretch. Offsetting this, debt remains sizable relative to equity (still ~0.8x), and the multi-year ROE profile shows profitability is not yet consistently strong.

Cash Flow

Cash generation improved materially after a weak FY2023, with FY2024 and FY2025 producing solid operating cash flow and positive free cash flow. Free cash flow has been meaningfully supportive relative to net income in the last two years, which helps earnings quality. The key risk is volatility: free cash flow was negative in FY2020 and FY2023, indicating sensitivity to working capital/capex cycles.

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	74.77B	73.25B	63.12B	65.08B	62.67B	59.14B
Gross Profit	19.24B	18.24B	13.15B	12.96B	15.72B	15.18B
EBITDA	9.10B	8.68B	5.85B	3.83B	7.98B	7.46B
Net Income	2.96B	2.58B	1.17B	-407.00M	2.49B	2.56B
Balance Sheet
Total Assets	94.19B	97.11B	94.54B	85.03B	86.47B	85.03B
Cash, Cash Equivalents and Short-Term Investments	15.44B	16.75B	16.13B	9.13B	12.22B	11.60B
Total Debt	29.98B	31.35B	35.14B	32.47B	30.87B	32.10B
Total Liabilities	50.29B	52.60B	53.24B	46.73B	46.08B	47.63B
Stockholders Equity	38.95B	38.73B	36.75B	34.35B	36.77B	34.65B
Cash Flow
Free Cash Flow	0.00	5.39B	4.59B	-2.11B	2.86B	557.00M
Operating Cash Flow	0.00	7.53B	7.09B	724.00M	5.52B	4.96B
Investing Cash Flow	0.00	-2.14B	-2.01B	-2.88B	-2.70B	-3.80B
Financing Cash Flow	0.00	-5.04B	1.65B	-1.03B	-2.34B	255.00M

DKS Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8230.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4461, the sentiment is Negative. The current price of 8230 is below the 20-day moving average (MA) of 10495.50, below the 50-day MA of 10246.80, and above the 200-day MA of 7016.26, indicating a neutral trend. The MACD of -554.38 indicates Positive momentum. The RSI at 27.61 is Positive, neither overbought nor oversold. The STOCH value of 3.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4461.

DKS Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4471	77 Outperform	¥109.42B	12.08	9.19%	3.33%	-17.97%	―
4971	74 Outperform	¥121.39B	18.74	―	0.93%	10.27%	-5.66%
4958	73 Outperform	¥112.20B	25.17	5.56%	2.59%	2.58%	-3.16%
4914	73 Outperform	¥118.69B	26.50	―	3.77%	9.07%	152.79%
4461	63 Neutral	¥80.10B	10.65	―	1.24%	8.78%	19.37%
4369	62 Neutral	¥84.52B	19.44	―	1.30%	47.56%	49.58%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

DKS Co., Ltd. Corporate Events

DKS Elevates Representative Director to Bolster SMART 2030 Execution

DKS Co., Ltd. announced that its Board of Directors has approved a change in the title of Representative Director SHIMIZU Shinji, effective April 1, 2026, promoting him from Representative Managing Director & CFO to Representative Senior Managing Director & CFO. The move is intended to expand his responsibilities, accelerate execution of the company’s medium-term management plan “SMART 2030,” and reinforce the management structure, signaling a governance-focused step to support long-term strategic objectives and operational execution.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen11990.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Co. Nominates Academic as New Outside Director to Bolster Governance

DKS Co., Ltd. has nominated academic Shigeki Sakurai, Professor Emeritus at Kyoto University and Kaishi Professional University, as a candidate for Outside Director, following a resolution by its Board of Directors on February 24, 2026. The appointment, which is subject to approval at the ordinary general meeting of shareholders scheduled for June 23, 2026, signals the company’s intent to strengthen its governance framework and incorporate external academic expertise into its board oversight.

If approved by shareholders, Sakurai’s addition to the board would expand independent perspectives within DKS’s top management structure, aligning the company with evolving corporate governance expectations on the Tokyo Stock Exchange Prime Market. The move may enhance stakeholder confidence in the company’s board independence and strategic decision-making, particularly as Japanese listed firms face increasing scrutiny over governance practices.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen11990.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Reshapes Organization and Management to Drive ‘SMART 2030’ Plan

DKS Co., Ltd. announced a series of organizational and personnel changes effective April 1, 2026, aimed at accelerating its medium-term management plan “SMART 2030.” The company will optimize divisional structures and enhance cross-functional collaboration to improve operational efficiency and competitiveness.

Key structural moves include creating a Business Planning Department within the Business Headquarters and forming a Planning & Marketing Department in the Life Sciences Headquarters by integrating planning and sales. DKS will also fold Biococoon Laboratories, Inc. into the Kyoto Central R&D Division to boost knowledge sharing, synergies, and R&D speed.

On the personnel side, multiple senior managers are being promoted or reassigned to align leadership with the new structure, including changes in finance, electronics and IT, life sciences, strategy planning, and R&D functions. These shifts are designed to strengthen execution of business strategies, sharpen customer responsiveness, and support long-term growth under the SMART 2030 framework.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen11990.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Launches New Shareholder Benefit Program to Strengthen Investor Loyalty

DKS Co. Ltd. has approved the introduction of a new shareholder benefit program for the next fiscal year, designed to reward investors holding at least 100 shares as of March 31 with tiered benefit points. These points can be redeemed via the DKS Premium Shareholder Benefit Club for over 4,000 items, including the company’s own products, gourmet foods, and gift cards, or converted into shared benefit coins that can be pooled with rewards from other listed companies.

In addition to the points system, all eligible shareholders will receive a special sales coupon granting access to DKS life sciences-related products at discounted prices, scheduled to be sent with dividend documents in late June 2026. The initiative is aimed at boosting the appeal of the company’s stock, promoting medium- to long-term shareholding, and deepening shareholder familiarity with DKS’s product lineup, which may enhance engagement and brand loyalty among its investor base.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen11990.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Corrects Fiscal-Year Labels in Interim Dividend Disclosure

DKS Co., Ltd. announced it has corrected previously released consolidated financial results for the six months ended September 30, 2025, after discovering errors in its dividend disclosure. The corrections revise the fiscal years associated with stated cash dividends per share, clarifying that the previously disclosed dividend figures and forecasts apply to the fiscal years ended and ending March 31, 2025 and March 31, 2026, rather than 2024 and 2025 as initially reported; the dividend amounts themselves, including the forecast of a total annual dividend of ¥140.00 for the year ending March 31, 2026, remain unchanged, limiting the impact to a clarification of timing rather than a change in shareholder returns.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Lifts Earnings and Dividend Forecast on Strong Electronics and Energy Demand

DKS Co., Ltd. has raised its consolidated forecast for the fiscal year ending March 31, 2026, projecting higher net sales and profits than previously expected, with all earnings indicators now set to exceed record levels achieved in the prior year. The upgrade reflects robust third‑quarter performance and sustained strong demand for low‑dielectric resins in high‑end servers and water‑based composite adhesives for battery negative electrodes, which are driving both top‑line growth and profitability. In line with these improved results and faster‑than‑planned progress on its mid‑term management plan “SMART 2030,” the company also increased its year‑end dividend forecast from ¥80 to ¥90 per share, lifting the expected annual dividend to ¥150 per share and signaling enhanced shareholder returns supported by stronger earnings momentum.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.

DKS Posts Strong Nine-Month Earnings and Lifts Full-Year Forecasts, Boosting Dividends

DKS Co., Ltd. reported strong consolidated results for the nine months ended December 31, 2025, with net sales up 10.9% year on year to ¥60.2 billion and profit attributable to owners of parent more than doubling to ¥4.2 billion, reflecting significant margin improvement and robust growth in comprehensive income. The company also strengthened its financial position, with total assets and equity rising and the equity ratio improving to 44.3%, and it raised both its full-year earnings and dividend forecasts for the fiscal year ending March 31, 2026, signaling confidence in sustained profit growth and a higher shareholder return policy.

The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.